MX2013013785A - Metodos para tratar lupus eritematoso sistemico, escleroderma y miositis con un anticuerpo contra el interferon alfa. - Google Patents

Metodos para tratar lupus eritematoso sistemico, escleroderma y miositis con un anticuerpo contra el interferon alfa.

Info

Publication number
MX2013013785A
MX2013013785A MX2013013785A MX2013013785A MX2013013785A MX 2013013785 A MX2013013785 A MX 2013013785A MX 2013013785 A MX2013013785 A MX 2013013785A MX 2013013785 A MX2013013785 A MX 2013013785A MX 2013013785 A MX2013013785 A MX 2013013785A
Authority
MX
Mexico
Prior art keywords
approximately
days
antibody
available
ifn
Prior art date
Application number
MX2013013785A
Other languages
English (en)
Spanish (es)
Inventor
Ryan Criste
Lorin Roskos
Wendy White
Dominique Ethgen
Rajesh Narwal
Gabriel Robbie
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MX2013013785A publication Critical patent/MX2013013785A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2013013785A 2011-05-25 2012-05-23 Metodos para tratar lupus eritematoso sistemico, escleroderma y miositis con un anticuerpo contra el interferon alfa. MX2013013785A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161489949P 2011-05-25 2011-05-25
PCT/US2012/039098 WO2012162367A1 (fr) 2011-05-25 2012-05-23 Procédés de traitement du lupus érythémateux systémique, de la sclérodermie et de la myosite par un anticorps contre l'interféron alpha

Publications (1)

Publication Number Publication Date
MX2013013785A true MX2013013785A (es) 2014-07-28

Family

ID=47217695

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013785A MX2013013785A (es) 2011-05-25 2012-05-23 Metodos para tratar lupus eritematoso sistemico, escleroderma y miositis con un anticuerpo contra el interferon alfa.

Country Status (9)

Country Link
EP (1) EP2714080A4 (fr)
JP (1) JP2014516970A (fr)
KR (1) KR20140043402A (fr)
CN (1) CN103732251A (fr)
BR (1) BR112013030242A2 (fr)
CA (1) CA2836926A1 (fr)
MX (1) MX2013013785A (fr)
RU (1) RU2013157177A (fr)
WO (1) WO2012162367A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2580301C1 (ru) * 2015-04-21 2016-04-10 Людмила Николаевна Хон Способ лечения системной красной волчанки человека

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2791170A1 (fr) 2011-12-16 2014-10-22 Synthon Biopharmaceuticals B.V. Composés et procédés pour traiter des maladies inflammatoires
WO2013101771A2 (fr) * 2011-12-30 2013-07-04 Genentech, Inc. Compositions et méthode pour le traitement de maladies auto-immunes
ES2745103T3 (es) * 2013-06-15 2020-02-27 Tocagen Inc Partículas inmunosupresivas similares a virus basadas en gammaretrovirus
CN103740755A (zh) * 2013-12-23 2014-04-23 中国农业大学 猪ifit1基因在抗prrs病毒中的应用
CN107058521B (zh) * 2017-03-17 2019-12-27 中国科学院北京基因组研究所 一种检测人体免疫状态的检测系统
EP3853859A1 (fr) * 2018-10-11 2021-07-28 Vivia Biotech, S.L. Procédé de détermination de l'efficacité d'un traitement avec une combinaison de médicaments chez un sujet diagnostiqué d'une maladie et procédé de classification de l'utilité de combinaisons de médicaments dans le traitement dudit sujet
JP2022512796A (ja) 2018-10-26 2022-02-07 ヤンセン バイオテツク，インコーポレーテツド Ｉ型インターフェロンシグネチャー及び使用方法
JP2022527542A (ja) * 2019-04-04 2022-06-02 ヤンセン バイオテツク，インコーポレーテツド 抗ＩＦＮ－α／ω抗体の投与方法
AU2023335547A1 (en) 2022-08-29 2025-02-27 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Method for screening and preparing immunomodulator
KR20250057823A (ko) 2022-08-29 2025-04-29 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Taci 폴리펩티드를 포함하는 융합 단백질 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
KR101225299B1 (ko) * 2003-12-10 2013-01-24 메다렉스, 인코포레이티드 인터페론 알파 항체 및 그의 용도
KR20080025174A (ko) * 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
NZ585064A (en) * 2007-11-05 2012-08-31 Medimmune Llc Methods of treating scleroderma
CN102083859B (zh) * 2008-05-07 2014-09-17 阿哥斯医疗公司 人源化抗人干扰素-α抗体
WO2010042705A1 (fr) * 2008-10-09 2010-04-15 Medimmune, Llc Formulation d'anticorps
KR20140048877A (ko) * 2011-04-26 2014-04-24 제넨테크, 인크. 자가면역 질환의 치료를 위한 조성물 및 방법

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2580301C1 (ru) * 2015-04-21 2016-04-10 Людмила Николаевна Хон Способ лечения системной красной волчанки человека

Also Published As

Publication number Publication date
WO2012162367A1 (fr) 2012-11-29
JP2014516970A (ja) 2014-07-17
CN103732251A (zh) 2014-04-16
EP2714080A1 (fr) 2014-04-09
BR112013030242A2 (pt) 2016-12-06
KR20140043402A (ko) 2014-04-09
RU2013157177A (ru) 2015-06-27
CA2836926A1 (fr) 2012-11-29
EP2714080A4 (fr) 2014-11-19

Similar Documents

Publication Publication Date Title
MX2013013785A (es) Metodos para tratar lupus eritematoso sistemico, escleroderma y miositis con un anticuerpo contra el interferon alfa.
KR102320059B1 (ko) 항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획
CN110769851B (zh) 兽用抗il31抗体
JP2025129151A (ja) イヌインターロイキン４受容体アルファに対する抗体
CA2607697C (fr) Traitement et evaluation des troubles inflammatoires
JP7008020B2 (ja) ヒトおよびイヌｉｌ－４ｒアルファに対するイヌ化ヒト抗体
KR20200015477A (ko) 신경 퇴행성 질환을 치료하기 위한 cd14 길항제 항체
JP2023506922A (ja) アトピー性皮膚炎を処置するための二重特異性イヌ化抗体
KR102527840B1 (ko) 인터페론 베타 항체 및 그의 용도
JP2021503888A (ja) 抗ｃｘｃｒ５抗体、その組成物及びその使用
KR20130137688A (ko) 베타7 인테그린 길항제를 투여하는 방법
US12528868B2 (en) CD1a antibodies and uses thereof
JP7202893B2 (ja) 炎症性腸疾患を治療する方法
JP2012530047A (ja) 多発性硬化症のための治療
US20220389089A1 (en) Anti-il-27 antibodies and uses thereof
AU2012258819A1 (en) Methods of treating systemic lupus erythematosus, scleroderma, and myositis with an antibody against interferon-alpha
RU2840044C1 (ru) Антитела к собачьему альфа-рецептору интерлейкина-4
AU2023279258A1 (en) Anti-bmp9 antibodies and methods of use thereof
WO2026094824A1 (fr) Utilisation d'un inhibiteur de pad pour le traitement ou la prévention de l'arthrite auto-immune
KR20230145929A (ko) CD1a 항체 및 그의 용도
CN118076635A (zh) 抗il-27抗体和其用途

Legal Events

Date Code Title Description
FA Abandonment or withdrawal